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Purpose:  Increasing  evidence  suggests  that  tear  hyperosmolarity  is  a  central  mechanism  causing  ocular  surface
inflammation and damage in dry eye disease. Mapracorat (BOL-303242-X) is a novel glucocorticoid receptor agonist
currently under clinical evaluation for use in the treatment of dry eye disease. This study assessed the anti-inflammatory
effects of mapracorat in an in vitro osmotic stress model which mimics some of the pathophysiological changes seen in
dry eye.
Methods: Human corneal epithelial cells were cultured in normal osmolar media (317 mOsM) or 440 mOsM hyperosmolar
media for 24 h. Luminex technology was used to determine the effect of mapracorat on hyperosmolar-induced cytokine
release. Effects of mapracorat on mitogen-activated protein kinase (MAPK) phosphorylation were determined by cell
based ELISA. Effects of mapracorat on nuclear factor kappa B (NFκB) and activator protein-1 (AP-1) transcriptional
activity were assessed by reporter gene assay. Dexamethasone was used as a control.
Results: Hyperosmolar conditions induced release of the pro-inflammatory cytokines interleukin-6 (IL-6), interleukin-8
(IL-8), and monocyte chemotactic protein-1 (MCP-1) from cultured human corneal epithelial cells, and altered the
phosphorylation state of p38 and c-Jun N-terminal kinase (JNK) and transcriptional activity of NFκB and AP-1. Incubation
of cells with mapracorat inhibited hyperosmolar-induced cytokine release with comparable activity and potency as
dexamethasone. This inhibition was reversed by the glucocorticoid receptor antagonist mifepristone (RU-486). Increased
phosphorylation of p38 and JNK caused by hyperosmolarity was inhibited by mapracorat. Mapracorat also significantly
decreased the hyperosmolar-induced increase in NFκB and AP-1 transcriptional activity.
Conclusions: Mapracorat acts as a potent anti-inflammatory agent in corneal epithelial cells challenged with osmotic
stress, with comparable activity to the traditional steroid dexamethasone. These in vitro data suggest that mapracorat may
be efficacious in the treatment of dry eye disease.
Dry eye disease is a common pathological condition,
involving tear film instability and epithelial damage which
leads to symptoms of discomfort and visual disturbances. A
central mechanism causing these alterations is an increase in
the osmolarity of the tears [1,2]. Tear osmolarity in dry eye
patients ranges from 306 to 441 mOsm, with an average of
343 mOsm, compared to ~302 mOsm in non-dry eye patients
[3]. However, a recent study suggests that transiently, tear
hyperosmolarity may be much higher when local tear film
thinning or breakup occur [4]. This increased osmolarity leads
to  a  cycle  of  inflammation,  further  exacerbating  dry  eye
symptoms [1,2].
In  vitro  cell  based  studies  have  demonstrated  that
exposure  of  the  corneal  epithelium  to  hyperosmolarity
increases  activation  of  mitogen  activated  protein  kinases
(MAPKs) such as c-Jun N-terminal kinase (JNK) and p38,
serine/threonine-specific  protein  kinases  that  respond  to
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extracellular stimuli and regulate various cellular activities
[5,6]. Experimental dry eye models have also demonstrated
an increase in MAPKs, especially JNK [7,8]. This leads to
increased activity of transcription factors such as activator
protein-1 (AP-1) and nuclear factor kappa B (NFκB) which
upregulate  pro-inflammatory  cytokine  production  in  the
ocular  surface  cells  leading  to  an  increase  in  release  of
cytokines into the tears. Increased levels of multiple cytokines
including interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor
necrosis factor-alpha (TNF-α) have been detected in both the
tear fluid of patients with dry eye symptoms [9-12] and also
in animal models of the disease [7,8,13]. These inflammatory
mediators then participate in the recruitment of immune cells
into the cornea and conjunctiva leading to a continuing cycle
of inflammation [14-16].
To date, the only FDA-approved drug for the treatment
of dry eye disease in the United States is cyclosporine A
(Restasis®) which is purported to act in part by inhibition of
T-cell-stimulated cytokines by binding to nuclear proteins
required for T-cell activation [17,18]. Topical corticosteroids
can be used for anti-inflammatory therapy for amelioration of
dry eye syndrome, however their long-term use is limited by
Molecular Vision 2010; 16:1791-1800 <http://www.molvis.org/molvis/v16/a195>
Received 27 July 2010 | Accepted 30 August 2010 | Published 2 September 2010
© 2010 Molecular Vision
1791the  fact  that  they  cause  side  effects  such  as  increased
intraocular pressure (IOP) and cataract formation [17,18].
Side  effects  of  traditional  steroids  are  mostly  due  to
transactivation-dependent gene regulation, whereas their anti-
inflammatory  properties  are  mediated  largely  via
transrepression. Recently, selective glucocorticoid receptor
agonists  (SEGRAs),  a  new  class  of  anti-inflammatory
compounds,  have  been  developed.  SEGRAs  promote  a
conformation  of  the  glucocorticoid  receptor  which
preferentially exhibits glucocorticoid-like anti-inflammatory
activities,  primarily  mediated  via  transrepression.  This
involves the modulation of the activation and/or activity of
transcription  factors  through  altered  protein–protein
interactions with co-regulatory proteins and promoter-bound
transcription  factors.  SEGRAs  exhibit  reduced  ability  to
transactivate than steroids and this is thought to be because
they exhibit lower glucocorticoid receptor-DNA interactions
than steroids. Therefore, these agents may offer a reduced
side-effect profile in comparison with classical steroids by
dissociation  between  transactivation  and  transrepression
[19-22].
Mapracorat  (also  known  as  BOL-303242-X  or  ZK
245186)  is  a  novel  SEGRA  compound  under  clinical
evaluation for the treatment of inflammatory skin and eye
diseases.  Mapracorat  showed  anti-inflammatory  efficacy
similar to traditional glucocorticoids in murine models of skin
inflammation and also in multiple ocular cell types [23,24]. It
exhibited  a  better  safety  profile  with  regard  to  growth
inhibition  and  induction  of  skin  atrophy  after  long-term
topical application, thymocyte apoptosis, hyperglycemia, and
hepatic tyrosine aminotransferase activity [23]. In trabecular
meshwork cells, mapracorat behaved as a partial agonist in
contrast to traditional glucocorticoids, in increasing myocilin,
a protein thought to be involved in steroid-induced glaucoma
[25].  Mapracorat  also  demonstrated  reduced  ability  to
increase  IOP  in  normotensive  rabbits  when  compared  to
dexamethasone [26].
The ability of mapracorat to reduce inflammation with
reduced side effects compared to classical steroids makes it
an attractive putative therapeutic for dry eye. Previous studies
have  demonstrated  that  hyperosmolarity  induces  an
inflammatory response in cultured human corneal epithelial
cells (HCEpiC) [5,27]. Furthermore, the efficacy of several
potential dry eye therapeutics has been tested using this model
[6,28,29]. Therefore, the current study investigated the anti-
inflammatory  properties  of  mapracorat  in  hyperosmolar-
stressed HCEpiC. The effect of mapracorat on hyperosmolar-
induced cytokine release was determined in both transformed
and  primary  HCEpiC.  To  investigate  the  mechanisms
underlying the anti-inflammatory properties of mapracorat, its
effects on p38 and JNK MAPKs activation and AP-1 and
NFκB transcriptional activity were also investigated.
METHODS
Reagents:  EpiLife  medium  and  human  corneal  growth
supplement  (HCGS),  penicillin-streptomycin  solution,
alamarBlue  solution,  Lipofectamine  LTX,  and  Opti-MEM
were obtained from Invitrogen (Carlsbad, CA). Mapracorat
(BOL-303242-X,  ZK245186;  R-1,1,1-trifluoro-4-(5-
fluoro-2,3-dihydrobenzofuran-7-yl)4-methyl-2-{[(2-
methyl-5-quinolyl)amino]methyl}pentan-2-ol) was provided
by Bayer Schering (Berlin, Germany). Dexamethasone was
from  Sigma  (St.  Louis,  MO)  and  IL-1β  was  from  R&D
Systems (Minneapolis, MN). Human multiplex-cytokine kits
were from Millipore (Billerica, MA). Cell-based FACE p38
and JNK ELISA kits were from Active Motif (Carlsbad, CA).
Cignal AP1 reporter (luc) and Cignal NFκB reporter (luc) kits
were purchased from SA Biosciences (Frederick, MD). Dual-
Glo Luciferase assay system was from Promega (Madison,
WI).  All  other  reagents  were  purchased  from  standard
commercial sources and were of the highest available purity.
Cells  and  treatments:  SV40-transformed  human  corneal
epithelial cells (T-HCEpiC) were received at passage 20 from
ATCC  (Manassas,  VA).  Primary  HCEpiC  (P-HCEpiC;
passage 2) were purchased from Invitrogen. Both of these cell
types were maintained in EpiLife medium supplemented with
HCGS, 100 U/ml of penicillin, and 100 µg/ml of streptomycin
at 37 °C in a humidified incubator with 5% CO2. Cells were
cultured  in  glucocorticoid-free  medium  (EpiLife  basal
medium  supplemented  with  12.5  µg/ml  bovine  pituitary
extract, 1.25 µg/ml bovine insulin, and 1.25 ng/ml EGF) for
48 h before exposure to hyperosmolar medium. Osmolarity
was increased to 440 mOsM by the addition of 123 mM
sucrose to basal EpiLife medium (at 317 mOsM). Osmolarity
of the solutions was verified using an osmometer (Osmette;
Advanced Instruments, Norwood, MA). Dexamethasone and
mapracorat stock solutions were prepared in DMSO. Each
treatment was performed in at least triplicate, and appropriate
dilutions were prepared to deliver a constant amount of the
vehicle to each well. Lack of an effect of treatments on cell
metabolic activity, an index of cell viability, was determined
by  the  alamarBlue  assay  [30,31].  A  summary  of  the
experiments performed in this study is shown in Table 1, as
outlined in detail below.
Cytokine  release  by  multiplex  Luminex:  T-HCEpiC  were
seeded  on  48-well  plates  at  a  density  of  2×104  cells;  P-
HCEpiC  were  seeded  on  24-well  plates  at  a  density  of
1.5×104 cells. After 72 h, cells were treated with vehicle (0.1%
DMSO), 10, 30, 100, 300, or 1,000 nM dexamethasone or
mapracorat for 24 h in 440 mOsM hyperosmolar basal media.
Cytokine content in the culture medium was analyzed using
multiplex Luminex bead technology [32,33] according to the
manufacturer's instructions. Briefly, 25 µl of medium samples
were incubated with antibody-coated capture beads overnight
at 4 °C. Washed beads were further incubated with biotin-
labeled  anti-human  cytokine  antibodies  for  1  h  at  room
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1792temperature  followed  by  incubation  with  streptavidin-
phycoerythrin  for  30  min.  Samples  were  analyzed  using
Luminex 200™ (Luminex, Austin, TX) and Statlia software
(Brendan Technologies Inc., Carlsbad, CA). Standard curves
of known concentrations of recombinant human cytokines
were used to convert median fluorescence intensity (MFI) to
cytokine concentration in pg/ml. Only the linear portions of
the  standard  curves  were  used  to  quantify  cytokine
concentrations.
p38, ERK, and JNK phosphorylation: Cells were seeded on a
96-well plate at a density of 1×104 cells per well. After 48 h,
the medium was replaced with basal medium for 18 h. Due to
the  short  incubation  time  necessary  for  measurement  of
MAPK  phosphorylation,  cells  were  pre-treated
with 0.1-10 µM mapracorat or dexamethasone for 2 h in basal
medium.  Cells  were  then  treated  with  isosmolar  media,
hyperosmolar media, or hyperosmolar media with 0.1-10 µM
mapracorat  or  dexamethasone  for  30  min.  Levels  of
phosphorylated  and  total  p38,  extracellular  signal-related
kinase  (ERK)  or  JNK  were  measured  using  a  cell  based
ELISA according to the manufacturer’s instructions. Briefly,
the cells were fixed with 4% formaldehyde in PBS. After
blocking,  cells  were  incubated  with  primary  antibodies
specific to the appropriate phosphorylated or total MAPK
overnight at 4 °C. Negative controls were performed using
secondary antibody only. After washing, cells were incubated
with HRP-conjugated secondary antibody for 1 h followed by
further  washing.  Chemiluminescent  reagent  was  added  to
each  well  and  the  resulting  luminescence  was  read  on  a
Synergy plate reader (Biotek, Winooski, VT). To verify that
cell number was unchanged by treatments, cells in each well
were further stained with crystal violet. The absorbance was
read on a Synergy plate reader at 595 nm. Data were expressed
as  the  ratio  of  phosphorylated  to  total  MAPK,  and  were
normalized by cell number.
AP-1 and NFκB transcriptional activity: AP-1 and NFκB
transcriptional activities were measured using an inducible
reporter construct which encoded a firefly luciferase reporter
gene under the control of a basal promoter element (TATA
box)  joined  to  tandem  repeats  of  specific  AP-1  or  NFκB
transcriptional response elements. This vector was mixed with
a constitutively expressing Renilla construct (which was used
as a normalizer) at a ratio of 40:1. pRSVT-HCEpiC were
seeded on a 96-well plate at a density of 1×104 per well. After
24 h, 200 ng of AP-1 or NFκB construct was transfected using
Lipofectamine  LTX  transfection  reagent.  Thirty  h  after
transfection, cells were treated with vehicle (0.1% DMSO),
440  mOsm  media  and/or  0.1  or  1  µM  mapracorat  or
dexamethasone  for  18  h  in  basal  medium.  Firefly  and
Renilla luciferase activity was measured using the Dual-Glo
luciferase assay system. Background relative luminescence
units (RLU) were subtracted and the ratio of firefly luciferase/
Renilla luciferase luminescence was then calculated.
Statistical  analysis:  Data  were  expressed  as  mean±SEM.
Statistical analysis was performed using a two-way ANOVA-
Contrast test with the statistical software JMP8 (SAS Institute,
Cary, NC). P values less than 0.05 were pre-determined to be
statistically significant. Concentration versus effect curves for
cytokines were plotted using averaged data from all samples.
Curve  fitting  was  conducted  to  estimate  the  IC50  for
dexamethasone  and  mapracorat  inhibition  of
hyperosmolarity-induced  IL-6  and  IL-8  release.  A  re-
parameterized four-parameter logistic equation was fit to the
data using similar methodology as that previously described
[34] using JMP8.
RESULTS
Mapracorat  reduced  hyperosmolarity-induced  cytokine
release  with  comparable  activity  to  dexamethasone:  The
effect of hyperosmolarity (440 mOsm) on release of IL-6,
IL-8, and MCP-1 in both transformed and primary corneal
epithelial cells was determined. IL-6 and MCP-1 release were
both significantly increased from T-HCEpiC treated with 440
mOsm  hyperosmotic  media  as  compared  to  317  mOsm
control (Figure 1). There was also a significant increase in
IL-8 and MCP-1 levels in the conditioned media from P-
HCEpiC exposed to hyperosmolarity (Figure 2).
There was a significant reduction in IL-6 levels measured
in the conditioned medium from T-HCEpiC exposed to 440
mOsm hyperosmotic media + all doses of mapracorat and
dexamethasone tested (1 – 1,000 nM) as compared to 440
TABLE 1. EXPERIMENTAL DESIGN SUMMARY.
  Experiments performed




















Technique Multiplex Luminex Multiplex Luminex Multiplex Luminex Cell-based ELISA Reporter gene assay
Cell type T-HCEpiC P-HCEpiC T-HCEpiC T-HCEpiC T-HCEpiC
Dose range of mapracorat
and dexamethasone
1–1000 nM 1–1000 nM 1–1000 nM 0.1–10 µM 0.1–1 µM
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1793mOsm media alone (Figure 1A). Hyperosmolarity-induced
(440 mOsm) increases in MCP-1 levels in the conditioned
medium were significantly reduced with 100 and 1,000 nM
mapracorat  and  with  10,  30,  100,  300,  and  1,000  nM
dexamethasone compared to 440 mOsm media alone (Figure
1B).  For  the  majority  of  treatments,  at  the  same  dose  of
mapracorat  and  dexamethasone,  there  was  no  significant
difference in IL-6 or MCP-1 release from T-HCEpiC. Only at
10 and 300 nM doses of mapracorat, the levels of MCP-1 were
significantly higher compared to those at the same doses of
dexamethasone. The IC50s for dexamethasone and mapracorat
inhibition of 440 mOsm hyperosmolarity-induced IL-6 and
MCP-1 were at nM levels. Estimated IC50s for IL-6 were 0.97
nM for mapracorat versus 0.38 nM for dexamethasone. The
IC50 values for dexamethasone and mapracorat inhibition of
IL-6 values were not significantly different from each other
based on overlapping confidence limits.
To confirm that the inhibitory effects of mapracorat on
cytokine  release  from  HCEpiC  were  mediated  via  the
glucocorticoid receptor, a widely used glucocorticoid receptor
anatagonist, RU-486 (mifepristone), was used. There was an
increase in both IL-6 (from 69.9±5.5 pg/ml to 100.8±4.7 pg/
ml) and MCP-1 (from 156.3±9.5 pg/ml to 438.2±10.3 pg/ml)
levels when cells were exposed to hyperosmolar (440 mOsm)
media. There was no effect of 1,000 nM RU-486 alone on 440
mOsm-induced  IL-6  (105.5±14.8  pg/ml)  or  MCP-1
(436.4±9.9 pg/ml) levels. In contrast, IL-6 and MCP-1 levels
in the conditioned media were significantly elevated after co-
treatment with 100 nM dexamethasone plus RU-468 at 100,
300, and 1,000 nM compared to 440 mOsm/dexamethasone
alone  (Figure  3).  Similarly,  co-incubation  of  440  mOsm
treated cells with 100 nM mapracorat plus either 100 or 1,000
nM RU-486 significantly increased IL-6 and MCP-1 release
compared to 440 mOsm/mapracorat alone (Figure 3). This
indicates that the anti-inflammatory properties of mapracorat
are mediated via the glucocorticoid receptor.
The effect of mapracorat was also determined in primary
HCEpiC (P-HCEpiC; Figure 2). There was a dose-dependent
inhibition of IL-8 release from P-HCEpiC with significant
reduction in hyperosmolarity-induced IL-8 at 30, 300, and
1,000  nM  mapracorat  and  100,  300  and  1,000  nM
dexamethasone  (Figure  2A).  Both  mapracorat  and
Figure 1. Mapracorat demonstrates similar activity to dexamethasone in inhibiting hyperosmolar-induced cytokine release in T-HCEpiC. Cells
were cultured in complete (HCGS containing) medium, followed by glucocorticoid-free medium for 48 h. Cells were then treated with 440
mOsm hyperosmotic basal media in the presence of dexamethasone or mapracorat for 24 h. IL-6 (A) and MCP-1 (B) release into the media
was analyzed by Luminex. Light gray bar represents control (317 mOsm); dark gray bar represents hyperosmolarity (440 mOsm); open circles
+ dashed line represent mapracorat; closed circles + solid line represents dexamethasone. For A, lines are the result of a re-parameterized
four-parameter logistic equation fit to the data; for B, lines are the linear interpolation between data points. Data are presented as mean±SEM,
n=3. *Versus 440 mOsm hyperosmotic media; #versus dexamethasone at the identical dose; p<0.05.
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1794dexamethasone  inhibited  hyperosmolarity-induced  MCP-1
release and a statistically significant effect on MCP-1 was
observed at doses as low as 10 nM (Figure 2B). As was the
case for T-HCEpiC, for the majority of treatments, at the same
dose  of  mapracorat  and  dexamethasone,  there  was  no
significant  difference  in  IL-8  or  MCP-1  release  from  P-
HCEpiC. For IL-6, only at 100 nM mapracorat, levels were
higher  than  at  100  nM  dexamethasone  and  at  30  nM
mapracorat, the levels of MCP-1 were higher as compared to
30 nM dexamethasone. The estimated IC50s for inhibition of
IL-8 release were estimated as 85 nM for mapracorat and 15
nM for dexamethasone, and, as observed for IL-6 and MCP-1
in  T-HCEpiC,  were  not  significantly  different  based  on
overlapping confidence limits. For MCP-1 the activities of
both compounds were close to maximal at 10 nM, making it
difficult to estimate IC50 values.
To confirm that these inhibitory effects of mapracorat on
cytokine release were not due to an effect on cell viability, an
alamarBlue assay was performed. There was no effect of
hyperosmolarity or any dose of mapracorat or dexamethasone
on cell viability in either cell type.
Mapracorat and dexamethasone suppress hyperosmolarity-
induced phosphorylation/activation of p38 and JNK MAPK:
To  investigate  the  underlying  mechanisms  of  the  anti-
inflammatory  effect  of  mapracorat,  its  effect  on
phosphorylation and therefore activation of hyperosmolar-
induced stress activated MAPKs were determined using cell-
based ELISAs. Exposure of T-HCEpiC to hyperosmolarity
(440  mOsM,  30  min)  induced  an  increase  in  the  ratio  of
phosphorylated to total p38 and JNK, indicating an increase
in  activity  of  these  inflammatory  signaling  mediators.  In
contrast, ERK phosphorylation was slightly decreased after
exposure  of  cells  to  hyperosmolar  medium  (ratio  of
phosphorylated  ERK:  total  ERK,  basal=0.87±0.04,
hyperosmolarity  treated=0.70±0.04,  p<0.05).  The  ratio  of
phosphorylated to total p38 was inhibited by 0.1 and 1.0 µM
of  mapracorat  and  dexamethasone  (Figure  4A).
Phosphorylated to total JNK ratio was also reduced by 10 µM
dexamethasone and both 1 and 10 µM mapracorat (Figure
Figure 2. Mapracorat demonstrates similar activity to dexamethasone in inhibiting hyperosmolar-induced cytokine release in P-HCEpiC. Cells
were cultured in complete (HCGS containing) medium, followed by glucocorticoid-free medium for 48 h. Cells were then treated with 440
mOsm basal media in the presence of dexamethasone or mapracorat for 24 h. IL-8 (A) and MCP-1 (B) release into the media was analyzed
by Luminex. Light gray bar represents control (317 mOsm); dark gray bar represents hyperosmolarity (440 mOsm); open circles + dashed
line represent mapracorat; closed circles + solid line represents dexamethasone. For A, lines are the result of a re-parameterized four-parameter
logistic equation fit to the data; for B, lines are the linear interpolation between data points. Data are presented as mean±SEM, n=3. *Versus
440 mOsm media; #versus dexamethasone at the identical dose; p<0.05.
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17954B). This indicates that hyperosmolar-induced activities of
both p38 and JNK can be inhibited by mapracorat.
Mapracorat  and  dexamethasone  reduce  hyperosmolarity-
induced  activation  of  NFκB  and  AP-1:  Glucocorticoids,
through binding to the glucocorticoid receptor, transrepress
both AP-1 and NFκB transcription factors [35]. In addition
MAPK p38 and JNK regulate production of cytokines through
activation of AP-1 [36]. To assess the effects of mapracorat
and  dexamethasone  on  the  activity  of  these  transcription
factors, luciferase reporter gene constructs containing tandem
repeats of NFκB or AP-1 specific transcriptional response
elements were transiently transfected into T-HCEpiC together
with  a  constitutively  expressing  Renilla  construct  as  a
normalizer. Cells were then treated with hyperosmolarity in
combination  with  either  mapracorat  or  dexamethasone.
Figure 5 shows that NFκB and AP-1 transcriptional activities
were  significantly  increased  by  hyperosmolarity  (440
mOsM). Mapracorat and dexamethasone at 0.1 or 1.0 µM
reduced this hyperosmolarity-induced transcriptional activity
to control levels (Figure 5).
DISCUSSION
Dry eye disease is known to be caused in part by an increase
in osmolarity of the tear film resulting in inflammation and
subsequent cell damage [1,2]. In both animal and cell based
studies, hyperosmotic stress has been shown to induce the
expression and production of pro-inflammatory cytokines in
the ocular surface cells [5-8]. The key finding of the current
study  is  that  mapracorat,  a  SEGRA  compound,  inhibited
hyperosmolarity-induced pro-inflammatory cytokines IL-6,
IL-8, and MCP-1 in HCEpiC, with comparable efficacy and
potency as dexamethasone. Two cell types were employed in
this  study,  human  primary  and  human  SV40  transformed
cells, and the profile of cytokines released by hyperosmolarity
differed between the two. While MCP-1 release was induced
in both types, IL-6 release was only induced in transformed
cells, while IL-8 release was increased only in primary cells.
The reason for these differences is unclear, however strain-
dependent differences in cytokine release have been observed
on the murine ocular surface in response to dessicating stress
[13].
IL-6 and IL-8 have been shown to be increased in the tears
of dry eye patients in multiple studies [9,10,12]. Inhibition of
Figure 3. Effect of RU-486 on mapracorat or dexamethasone inhibition of hyperosmolarity-induced cytokine release in T-HCEpiC. Cells were
cultured in complete (HCGS containing) medium, followed by glucocorticoid-free medium for 48 h. Cells were treated with 440 mOsm
hyperosmotic basal media + RU486 and/or mapracorat or dexamethasone for 24 h. Cytokine release into the media was analyzed by Luminex.
A: IL-6 release; B: MCP-1 release. For both A and B, the white bar represents 440 mOsm + 100 nM mapracorat and the black bar represents
440 mOsm + 100 nM dexamethasone; open circles + dashed line represents 440 mOsm + mapracorat + RU-486; closed circles + solid line
represents 440 mOsm + dexamethasone + RU-486, dark gray bar represents 440 mOsm alone. Data are presented as mean±SEM, n=3. *Versus
respective 440 mOsm + mapracorat or 440 mOsm + dexamethasone; for IL-6, dark gray 440 mOsm bar denotes significantly different from
440 mOsm + dexamethasone and 440 mOsm + mapracorat; for MCP-1, dark gray 440 mOsm bar denotes significantly different from 440
mOsm + dexamethasone; p<0.05.
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1796the receptor for MCP-1, chemokine receptor 2, with a topical
agonist significantly improved dry eye disease in a murine
model, demonstrating the importance of this cytokine in the
pathology  of  dry  eye  [37].  We  demonstrated  that  these
inhibitory  effects  of  mapracorat  on  cytokine  release  were
mediated via the glucocorticoid receptor, by reversal using
RU-486, a synthetic steroid that antagonizes glucocorticoids
such as dexamethasone by competing for the ligand binding
site [38]. These data are in agreement with a previous study
in  HCEpiC  which  demonstrated  that  IL-1β-stimulated
cytokine release could be inhibited by mapracorat [24].
The  MAPK  cascades  are  serine/threonine-specific
kinases which play a key role in regulating the production of
proinflammatory  cytokines  leading  to  inflammation  [39].
While JNK and p38 are stimulated by predominantly stress-
related  stimuli  such  as  osmotic  and  redox  stress  and  UV
radiation,  ERK  is  activated  through  proliferative  and
mitogenic stimuli [39]. Previous studies have demonstrated
that hyperosmolar-induced cytokine release in HCEpiC is
mediated via multiple MAPKs including ERK, JNK, and p38
[5,6]. We found that both JNK and p38 were stimulated by
hyperosmolarity  and  inhibited  by  mapracorat  to  a  similar
extent as dexamethasone. In contrast, we did not detect any
increase  in  ERK  phosphorylation  in  response  to
hyperosmolarity.
The transcription factors NFκB and AP-1 play a major
role in the induction of genes involved in inflammation such
as cytokines, cytokine receptors, chemotactic proteins and
adhesion  molecules  [35].  In  HCEpiC  exposed  to
hyperosmolarity,  p38  is  known  to  regulate  NFκB  activity
[28], while increased JNK activity leads to stimulation of
AP-1  activation  through  activation  of  Jun  [27,36].  In  the
current study we demonstrated that hyperosmolarity-induced
transcriptional activities of AP-1 and NFκB were inhibited by
mapracorat.  This  demonstrates  that  the  anti-inflammatory
effects of mapracorat are mediated by effects on multiple
signaling pathways.
Like  traditional  steroids,  SEGRAs  are  glucocorticoid
receptor ligands that promote transrepression giving them
potent anti-inflammatory properties [40,41]. SEGRAs, like
glucocorticoids,  transrepress  transcription  factors  such  as
AP-1 and NFκB by a tethering mechanism or by competition
for nuclear co-activators between the GR complex and the
transcription factors [40,42,43]. Another mechanism for the
reduced  AP-1  activity  may  be  through  the  glucocorticoid
receptor  binding  to  JNK  leading  to  suppression  of  JNK
Figure 4. Effects of mapracorat and dexamethasone on hyperosmolarity-induced phosphorylation of p38 and JNK in T-HCEpiC. Cells were
cultured in complete (HCGS containing) medium, followed by basal medium for 20 h. Cells were pre-treated with dexamethasone or
mapracorat for 2 h. Cells were then treated with 440 mOsm hyperosmotic media + dexamethasone or mapracorat for 30 min. Phosphorylated
p38 (A) and JNK (B) concentrations were determined by cell-based ELISA. Data are presented as mean±SEM, n=6. *Versus 440 mOsm
media; p<0.05.
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1797activity  and  subsequent  inhibition  of  AP-1  [40].  The  GC
receptor  also  inhibits  the  JNK  and  p38  pathway  through
increased  expression  of  the  MAP  kinase  phosphatase-1
(MKP-1)  which  may  contribute  to  the  reduced  NFκB
transcriptional  activity  [44-46].  This  increase  in  MKP-1
activity is not due to direct binding of the GC receptor to DNA
at a GC response element, rather, it is likely mediated by a
tethering mechanism involving the glucocorticoid receptor
and an enhancer-binding protein which binds to the MKP-1
promoter [47].
SEGRAs exhibit reduced ability to transactivate through
glucocorticoid  receptor-DNA  interactions  [40,41].  This
confers  a  major  advantage  of  SEGRAs  over  traditional
glucocorticoids in that they can offer a reduced side effect
profile  while  maintaining  anti-inflammatory  properties
through transrepression. Mapracorat exhibits a better safety
profile with regard to growth inhibition and induction of skin
atrophy  after  long-term  topical  application,  thymocyte
apoptosis,  hyperglycaemia,  and  hepatic  tyrosine
aminotransferase  activity  [23]  in  animal  models.  Of
importance  in  its  use  for  ocular  indications,  mapracorat
increases IOP in rabbits to a lower extent than dexamethasone
and increases the expression of myocilin, a protein thought to
be involved in the progression of glaucoma, to a significantly
lesser extent than classic steroids [25,26].
In summary this study demonstrates that a novel SEGRA
compound currently under clinical development, mapracorat,
decreases  hyperosmolarity-induced  cytokine  release  with
similar  efficacy  and  potency  as  dexamethasone.  This
inhibition is likely mediated by reduction of the activation of
MAPKs JNK and p38 and transcriptional activity of AP-1 and
NFκB.  Given  preclinical  evidence  that  mapracorat
demonstrates a reduced side-effect profile in the eye, these in
vitro  results  demonstrate  the  therapeutic  potential  for
mapracorat in the treatment of dry eye disease.
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